Drug intelligence / Profile preview

AD100

Development stage: Unknown
Modality: Vaccines & Immunotherapeutics, Cell Therapies
Administration: Intradermal

Overview

AD100 is an allogeneic tumor vaccine designed for the treatment of advanced non-small-cell lung cancer. It is based on an adenocarcinoma cell line (AD100) that has been genetically modified through transfection to express the co-stimulatory molecule B7.1 (CD80) and human leukocyte antigen (HLA) A1 or A2. This modification aims to enhance the presentation of tumor antigens and provide co-stimulation to T-cells, thereby eliciting a robust anti-tumor immune response.

Other names: Ad100-B7.1/HLA

Beyond the preview

Go deeper on AD100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD100.